Monopar Therapeutics Inc.

06/23/2026 | Press release | Distributed by Public on 06/23/2026 06:01

Proxy Results (Form 8-K)

Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 22, 2026, Monopar Therapeutics Inc. ("Monopar" or the "Company") held its Annual Meeting. A total of 6,698,778 shares of the Company's common stock were entitled to vote as of April 27, 2026, the record date for the Annual Meeting, of which 5,760,392 shares were represented in person or by proxy at the Annual Meeting. At the Annual Meeting, the stockholders of the Company voted on the following proposals:
(1) the election of six directors to the Company's Board of Directors to serve until the Company's next annual meeting of stockholders or until their respective successors are duly elected and qualified;
(2) the approval of the compensation of the Company's named executive offers ("NEOs") on an advisory, non-binding basis;
(3) the approval of the Company's 2026 Stock Incentive Plan; and
(4) the ratification of the selection of BPM LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026.
2
Proposal 1 -Election of Directors
At the Annual Meeting, the voting results with respect to the proposal for the election of directors, included in the Company's Proxy Statement on Schedule 14A for the Annual Meeting, were as follows:
Director
For
Withheld
Broker Non-Votes
Christopher M. Starr, Ph.D.
4,203,485
757,652
799,255
Chandler D. Robinson, MD MBA MSc
4,447,108
514,029
799,255
Raymond W. Anderson, MBA MS
4,671,362
289,775
799,255
Kim R. Tsuchimoto
4,325,379
635,758
799,255
Lavina Talukdar, CFA
4,897,733
63,404
799,255
Nicole Sweeny
4,911,758
49,379
799,255
Accordingly, each of the foregoing persons was elected as a director at the Annual Meeting.
Proposal 2 -Approval of the Compensation of the Company's Named Executive Officers on an Advisory, Non-Binding Basis
The voting results with respect to the proposal to approve the compensation of the Company's NEOs on an advisory, non-binding basis, were as follows:
For
Against
Abstain
Broker Non-Votes
4,355,628
604,858
651
799,255
Accordingly, the Company's stockholders approved the compensation of the Company's NEOs on an advisory, non-binding basis.
Proposal 3 -Approval of the Company's 2026 Stock Incentive Plan
The voting results with respect to the proposal to approve the Company's 2026 Stock Incentive Plan were as follows:
For
Against
Abstain
Broker Non-Votes
4,444,209
516,570
358
799,255
Accordingly, the Company's stockholders approved the Company's 2026 Stock Incentive Plan.
Proposal 4 -Ratification of the Company's Selection of Independent Registered Public Accounting Firm
The voting results with respect to the proposal to ratify the selection of BPM LLP to serve as the Company's independent registered public accounting firm for the year ending December 31, 2026, were as follows:
For
Against
Abstain
Broker Non-Votes
5,759,198
998
196
N/A
Accordingly, the Company's stockholders ratified the selection of BPM LLP to serve as the Company's independent registered public accounting firm for the year ending December 31, 2026.
No other matters were submitted to a vote of stockholders at the Annual Meeting.
3
Monopar Therapeutics Inc. published this content on June 23, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on June 23, 2026 at 12:01 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]